arrow_back Back Filing freshness 10-Q Q1 FY2026 SEC EDGAR

MACROGENICS INC

MGNX
$4.04 ▲ +0.03 (+0.75%) at close
Healthcare ·Pharmaceutical Preparations ·USPharmaceutical Preparations
57 Visible periods
28 Metrics
Peer-ranked Benchmarks
Price Chart
16
Health
Poor
Bearish
auto_awesome

Analytical Summary

MACROGENICS INC faces fundamental challenges with weakness in Return on Common Equity (%) and Profit Margin (%). The fundamentals warrant careful consideration of downside risks.

Market Cap $256.3M
Dividend Yield
Revenue Growth 57.5%
Op. Margin -161.0%
ROIC -124.6%
FCF / Share $-0.57
Trailing P/E
Price / Book 12.1x
FCF Yield
Debt / Equity
info Valuation on last close. End-of-day price, Aug 7, 2026.

57-Year Financial Trajectory

Quarterly
Metric Value Trend Year over Year Percentile
Revenue Total top-line sales
$20.77M
↑ +57.5%
Net Income Profit after all expenses
$-36.77M
↑ +10.4%
Operating Margin Operating profit as % of sales
-161.0%
↓ -448.6% 5th
FCF / Share Free cash flow per share
$-0.57
↑ +24.3%
trending_up

Bullish Indicators

  • No bullish signals detected.
warning

Bearish Risks

  • Operating Margin (%)Operating Margin (%) is in the bottom quartile
  • Profit Margin (%)Profit Margin (%) is in the bottom quartile
  • Return on Common Equity (%)Return on Common Equity (%) is in the bottom quartile

Health Breakdown

Profitability
5
Returns
6
Cash Quality
70

bar_chart Data from SEC EDGAR XBRL filings

Synced 1 week ago 16 years · 57 quarters